Oppenheimer Maintains Outperformer on UroGen Pharma, Raises Price Target to $50

Benzinga Newsdesk www.benzinga.com Positive 90.7%

Neg 0% Neu 0% Pos 90.7%

Oppenheimer analyst Leland Gershell maintains UroGen Pharma (NASDAQ:URGN) with a Outperformer and raises the price target from $40 to $50.